Want to see HTFL full AI Analyst Report?
HTFL Stock Chart & Stats
$24.12
$0.48(1.99%)
At close: 4:00 PM EDT
$24.12
$0.48(1.99%)
Day’s Range― - ―
52-Week Range$20.13 - $50.48
Previous CloseN/A
Volume122.43K
Average Volume (3M)1.81M
Market Cap
$4.07B
Enterprise Value$2.40K
Total Cash (Recent Filing)$162.55M
Total Debt (Recent Filing)$27.13M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Nov 18, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding86,953,630
10 Day Avg. Volume1,108,416
30 Day Avg. Volume1,809,716
Financial Highlights & Ratios
PEG Ratio2.03
Price to Book (P/B)8.27
Price to Sales (P/S)14.12
P/FCF Ratio-42.10
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$40.25Price Target Upside66.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$230.06M
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthRapid revenue expansion indicates increasing adoption of HeartFlow’s diagnostic service and a growing installed base. Raised guidance and higher case volumes support a durable multi-quarter growth trajectory rather than an isolated improvement.
Strong And Expanding Gross MarginsHigh and improving gross margins demonstrate attractive software-driven unit economics. AI efficiencies, increasing volume, and a richer Plaque product mix could support further operating leverage as utilization expands across the customer base.
Clinical Differentiation And Product AdoptionA substantial clinical evidence base and differentiated diagnostic capabilities can strengthen physician trust, reimbursement discussions, and customer retention. These advantages create barriers to adoption for competing cardiac imaging solutions.
Bears Say
Persistent Operating And Net LossesHeartFlow remains materially unprofitable despite strong revenue growth and margin expansion. The elevated expense base means additional scale is still required before gross-profit gains translate into sustainable operating and net profitability.
Continued Cash BurnNegative operating and free cash flow indicate that the business has not yet funded itself internally. Although burn is improving, continued dependence on its cash balance or future financing could constrain flexibility before the targeted 2028 profitability milestone.
Legal And Regulatory OverhangLong-running intellectual-property and government matters can consume management attention, increase legal costs, and introduce uncertainty around operations or commercialization. Their extended timelines make the overhang relevant across the medium-term outlook.
HeartFlow, Inc. News
HTFL FAQ
What was HeartFlow, Inc.’s price range in the past 12 months?
HeartFlow, Inc. lowest stock price was $20.13 and its highest was $50.48 in the past 12 months.
What is HeartFlow, Inc.’s market cap?
HeartFlow, Inc.’s market cap is $4.07B.
When is HeartFlow, Inc.’s upcoming earnings report date?
HeartFlow, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 87 days.
How were HeartFlow, Inc.’s earnings last quarter?
HeartFlow, Inc. released its earnings results on Aug 13, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.134 by $0.064.
Is HeartFlow, Inc. overvalued?
According to Wall Street analysts HeartFlow, Inc.’s price is currently Undervalued.
Does HeartFlow, Inc. pay dividends?
HeartFlow, Inc. does not currently pay dividends.
What is HeartFlow, Inc.’s EPS estimate?
HeartFlow, Inc.’s EPS estimate is -0.11.
How many shares outstanding does HeartFlow, Inc. have?
HeartFlow, Inc. has 86,953,630 shares outstanding.
What happened to HeartFlow, Inc.’s price movement after its last earnings report?
HeartFlow, Inc. reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.134. Following the earnings report the stock price went up 35.698%.
Which hedge fund is a major shareholder of HeartFlow, Inc.?
Currently, no hedge funds are holding shares in HTFL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeartFlow, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.25 (66.87% Upside)
$40.25 (66.87% Upside)
Blogger Sentiment
Bullish
HTFL Sentiment 86%
Sector Average 57%
Sector Average 57%
Hedge Fund Trend
Decreased
By 68.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 12.0%
Last 30 Days ▲ 26.4%
Last 30 Days ▲ 26.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
116.15%
Trailing 12-Months
Company Description
HeartFlow, Inc.
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.
HTFL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong top-line momentum (48% YoY Q2 revenue growth), significant gross-margin expansion (770 bps YoY) and raised full-year guidance, supported by accelerating Plaque adoption, durable FFRCT utilization, a rich clinical evidence base, and a clear R&D pipeline. Offsets include remaining GAAP losses, early-stage Plaque penetration relative to its long-term potential, ongoing litigation, and pricing/ASP dynamics that could moderate in 2027. On balance, operational and financial progress, upgraded guidance, and a solid cash position outweigh the near-term risks.View all HTFL earnings summariesHTFL Stock 12 Month Forecast
Average Price Target
$40.25
▲(66.87% Upside)
Technical Analysis
Ownership Overview
23.27% Insiders
27.21% Mutual Funds
1.17% Other Institutional Investors
36.51% Public Companies and
Individual Investors